FY2025 · ended Dec 31, 2025 · Revenue $3.18B, +10.6% YoY · Filed Feb 25, 2026
United Therapeutics Corporation (UTHR) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.2 billion and net income of $1.3 billion. Free cash flow was $1.0 billion.
Revenue (TTM)
$3.19B
+1.9% vs year-ago TTM
Net income (TTM)
$1.23B
-3.2% vs year-ago TTM
Operating cash flow (TTM)
$1.43B
-8.1% vs year-ago TTM
Free cash flow (TTM)
$867.20M
-22.7% vs year-ago TTM
EPS (TTM)
$26.52
+0.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
43.83M
-2.4% vs prior year
Net cash
$2.25B
FY 2019
Operating margin
41.4%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- UTHR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Silver Spring, MD
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1082554
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.2B | $2.9B | $2.3B | $1.9B | $1.7B |
| Operating income | $1.5B | $1.4B | $1.2B | $979.7M | $555.9M |
| Net income | $1.3B | $1.2B | $984.8M | — | — |
| Diluted EPS | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 |
| Operating cash flow | $1.6B | $1.3B | $978.0M | $802.5M | $598.2M |
| Free cash flow | $1.0B | $1.1B | $747.6M | $663.7M | $477.4M |
| Total assets | $7.9B | $7.4B | $7.2B | $6.0B | $5.2B |
| Total liabilities | $783.8M | $920.0M | $1.2B | $1.2B | $1.2B |
| Stockholders' equity | $7.1B | $6.4B | $6.0B | $4.8B | $4.0B |
| Cash and investments | $4.7B | $4.7B | $4.9B | $4.2B | $3.6B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 21, 2026 |
| 8-K |
Current report
Other events
|
Oct 14, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
All 1002 United Therapeutics Corporation SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.